What are the fundraising trends in the synthetic biology market?

In our synthetic biology market deck, you will find everything you need to understand the market

This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market

Is more or less capital going into the synthetic biology market?

Less capital is going into the synthetic biology market so far in 2026, even though the cleaner full-year comparison between 2024 and 2025 looked positive. Year-to-date 2026 funding reached $276.4M, down from $407.1M over the comparable period in 2025, which is a decline of roughly one-third.

The latest comparison deserves the most weight for current momentum because it uses the same January through early July window. The synthetic biology market has not stopped producing deals, but investors are committing less capital per deal.

The full-year context is more constructive. Full-year 2025 funding reached $789.2M across 29 deals, up from $642.9M across 21 deals in 2024. That means the synthetic biology market expanded on an annual basis from 2024 to 2025.

The tension is important. The 2025 annual increase shows that synthetic biology was not structurally abandoned, but the 2026 year-to-date slowdown shows that the recovery did not keep accelerating. The market is still active, but the capital environment has tightened.

The strongest evidence is round-size compression. The average year-to-date round fell from $29.1M over the comparable 2025 period to $16.3M in 2026, while the median fell from $19.0M to $9.5M. That means the decline is not only about one missing mega-round; the typical funded company is also raising less.

For the full company-level funding tracker and category details, see the full synthetic biology market report.

Is synthetic biology funding activity driven by more deals or larger rounds?

Synthetic biology funding activity is currently being driven by more deals, not larger rounds. Year-to-date 2026 had 17 qualifying deals, up from 14 over the comparable 2025 period, but total capital fell from $407.1M to $276.4M.

That combination is decisive. More companies are raising, but each company is generally receiving a smaller check. The synthetic biology market has more breadth than capital depth right now.

The round-size evidence confirms the point. The average round fell from $29.1M to $16.3M, and the median round fell from $19.0M to $9.5M. The median matters because it shows what the ordinary funded company is experiencing, not just what the largest deals are doing.

The full-year comparison points in the same direction. Funding rose from $642.9M in 2024 to $789.2M in 2025, but deal count rose faster, from 21 deals to 29 deals. Average round size fell from $30.6M to $27.2M, and median round size fell from $17.2M to $11.7M.

The practical takeaway is that synthetic biology investors are still willing to fund many companies, but they are less willing to write large platform checks unless the company has unusually strong proof around clinical value, manufacturing readiness, cost reduction, or customer demand.

Is synthetic biology capital moving toward later-stage or earlier-stage companies?

Synthetic biology capital is moving somewhat toward later-stage or more validated companies, even though early-stage deal formation remains active. In year-to-date 2026, Seed and Series A rounds made up most of the deal count, but Series B and Series C rounds still captured 37.1% of capital.

The 2026 stage split looks early by deal count and more mature by dollars. Seed rounds were 35.3% of deals but only 9.3% of capital, which means investors are still forming new companies but keeping early checks small.

Series A was the largest year-to-date 2026 stage by capital, with $125.7M, or 45.5% of funding. Series C contributed another $74.0M, or 26.8%. That puts the market’s capital center of gravity around companies that have moved beyond initial formation.

The full-year trend also points toward selective maturation. In 2024, Seed, Series A, and Unknown rounds captured 73.8% of capital, while Series B+ captured 26.2%. In 2025, Seed, Series A, and Unknown rounds fell to 66.1%, while Series B+ rose to 34.0%.

The synthetic biology market is not yet a late-stage market, but it is becoming more proof-sensitive. Investors still back early companies, but the major dollars increasingly go to companies with prior validation, regulatory direction, manufacturing progress, or clinical translation potential.

This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms

Is the synthetic biology market maturing or still experimental?

The synthetic biology market is still experimental in company formation, but it is maturing in investor behavior. Year-to-date 2026 included 6 seed rounds and 5 Series A rounds, so early formation remains active, but the largest checks are going to companies with clearer validation paths.

The median year-to-date 2026 round was $9.5M, which is not the profile of a broadly mature scale-up market. Most companies are raising milestone capital, not enough money to fully de-risk commercial manufacturing, clinical development, or global deployment.

At the same time, the biggest rounds are no longer generic “bioeconomy” financings. They are tied to specific proof narratives: human cell programming, synthetic-biology-enabled therapeutics, precision-fermentation dairy proteins, advanced biosynthesis for pharmaceutical ingredients, continuous fermentation, and intracellular delivery infrastructure.

Full-year 2025 reinforces the same interpretation. Series A was the largest stage by both capital and deal count, with 9 deals and $374.9M. That is a translation-stage profile: companies are moving from platform promise toward technical proof, customer validation, regulatory strategy, and scale-up.

The synthetic biology market is therefore selectively maturing rather than mature. The science and business models remain risky, but investors are applying more mature filters and rewarding companies that can explain exactly which biological design, manufacturing, clinical, or industrial bottleneck they solve.

Are new startups still entering the synthetic biology market?

Yes, new startups are still entering the synthetic biology market, but the current-year signal is much weaker in capital terms than the 2025 signal. First financings represented 35.3% of year-to-date 2026 deals, but only 11.2% of capital.

That means new-company formation is alive, but new companies are not receiving the biggest checks. The first-financing group in 2026 includes companies such as Biographica, Anzen Industries, Twogee Biotech, Fermeate, Melazyme, and StrainX Bioworks, mostly at seed or early Series A scale.

The comparable 2025 period was much stronger for new entrants. First financings were 50.0% of deals and captured 49.4% of capital over the comparable period, helped by large first financings or launches such as Latent Labs, Vivici, Synthetic Design Lab, Trilobio, Differential Bio, and Stylus Medicine.

The full-year comparison also shows that 2025 was unusually open to new company formation. First financings rose from 23.8% of deals in 2024 to 37.9% in 2025, and first-financing capital rose from 28.0% to 38.0%.

The practical interpretation is that the synthetic biology market is still open to new startups, but the bar for large first checks has moved higher. Investors are still buying exposure to new ideas, but they are reserving major capital for companies that have already passed earlier technical or commercial screens.

For a deeper look at new-company formation and follow-on funding patterns, see the synthetic biology market deck.

Are more investors entering the synthetic biology market?

More investors appear active in the synthetic biology market so far in 2026 than over the comparable 2025 period, but the longer annual comparison is more cautious. Year-to-date 2026 had about 90 unique disclosed investors, compared with about 43 over the comparable 2025 period.

The number of tier-1 investors also rose in the freshest comparison, from about 20 over the comparable 2025 period to 26 in year-to-date 2026. That matters because the increase is not only coming from small incidental syndicate participants.

But full-year 2025 did not show a structural expansion versus 2024. Full-year 2025 had about 95 unique disclosed investors, down from 119 in 2024, even though 2025 had more deals. Unique tier-1 investors also slipped from 41 in 2024 to about 37 in 2025.

The best explanation is that the synthetic biology investor base remains broad but inconsistent. Some 2026 rounds had long disclosed syndicates, which lifts the unique-investor count, but repeat participation remains limited.

The synthetic biology market is attracting many investors selectively rather than building a dense specialist-investor base. Many funds are willing to join a strong company-specific round, but few appear to be making broad programmatic commitments across the whole market.

This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups

Are top investors getting more or less active in synthetic biology?

Top investors are more active than they were in 2024, but year-to-date 2026 does not yet show a new step-change in repeat activity. In 2024, only KdT Ventures and Digitalis Ventures appeared in more than one qualifying deal. In full-year 2025, repeat activity broadened, with SOSV appearing in 3 deals and several investors appearing in 2.

That 2025 increase matters because it suggests some specialist, deeptech, climate, food, and biotech investors were willing to make multiple synthetic biology bets. Repeat names included RA Capital Management, Khosla Ventures, ReGen Ventures, Main Sequence, European Innovation Council Fund, Azolla Ventures, and Zero Carbon Capital.

The 2026 year-to-date picture is more modest. So far in 2026, only SOSV and Good Startup appear in more than one qualifying disclosed deal. That is similar to the comparable 2025 period, when RA Capital Management and Khosla Ventures were the only repeat names.

The real signal is that top investors are active, but not dominant. The synthetic biology market still looks syndicate-heavy and fragmented, with many investors joining specific rounds rather than repeatedly backing the category across multiple subsegments.

So top-investor activity improved in 2025 versus 2024, but the synthetic biology market has not consolidated around a small group of obvious category leaders. A marquee investor in one deal should be read as validation of that company, not proof that the entire category has been broadly rerated.

Which synthetic biology subcategories are gaining momentum?

Synthetic Biology Therapeutics is the clearest subcategory gaining capital momentum. The category captured $292.9M, or 37.1% of full-year 2025 capital, and then increased to 43.2% of year-to-date 2026 capital.

The therapeutics signal is stronger than the deal-count signal. In year-to-date 2026, Synthetic Biology Therapeutics represented only 17.6% of deals but 43.2% of funding, giving it the highest capital-share-to-deal-share ratio of any category. Investors are writing disproportionately large checks when synthetic biology maps to high-value clinical or cell-programming markets.

Synbio Food Platforms also show activity momentum, though not the same capital intensity. Food platforms had the highest full-year 2025 deal count and tied for the highest year-to-date 2026 deal count. The category’s year-to-date 2026 capital share was 24.1%, close to its deal share, which means the category is active but not dramatically overfunded.

Engineered Microbes are also gaining relevance. The category had 5 deals in full-year 2025 and already had 4 deals by early July 2026, with capital share rising from 11.2% in 2025 to 17.0% in year-to-date 2026.

Biofoundry Platforms are gaining strategic relevance by deal count, but not yet by dollars. The category already matched its full-year 2025 deal count by early July 2026, but it captured only 8.8% of current-year capital. That suggests infrastructure is increasingly important, but investors are still not funding it at the scale they fund therapeutics.

The most useful category breakdown is available in the deeper analysis of the synthetic biology market.

Which synthetic biology subcategories are losing momentum?

Synbio Design Software is the clearest subcategory losing visible momentum so far in 2026. It raised $257.0M in 2024, or 40.0% of total capital, then $230.8M in 2025, or 29.2%, but only $9.5M in year-to-date 2026, or 3.4%.

That decline is important because Synbio Design Software was one of the strongest narratives in 2024 and 2025. EvolutionaryScale, Cradle, Profluent, Latent Labs, Ansa, and Aether supported the idea that AI-enabled biological design was one of the most fundable parts of synthetic biology.

The decline does not mean investors have rejected AI biology. A better interpretation is that several leading AI-biology platforms already raised large rounds in 2024 and 2025, and the next financing cycle will require stronger evidence that model outputs translate into useful biological products, therapeutic programs, or industrial workflows.

Synbio Materials Platforms also remain weak. Materials raised $81.6M in 2024, helped by larger rounds such as Constructive Bio and Insempra, but only $18.4M in full-year 2025 and $9.7M in year-to-date 2026.

Biofoundry Platforms are not losing activity, but they remain weak on capital intensity. The category’s funding is modest relative to the market’s stated need for better automation, fermentation control, and scale-up infrastructure.

This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology

Which regions are gaining momentum in synthetic biology funding?

Europe is the region gaining the most visible momentum in the synthetic biology market. Europe captured $136.25M, or 49.3% of year-to-date 2026 capital, compared with $105.0M and 25.8% over the comparable 2025 period.

Europe also improved by deal count. The region produced 8 deals so far in 2026, compared with 5 over the comparable 2025 period. That means Europe is gaining on both capital and company activity, not just on one large round.

The shift looks even bigger against full-year 2025. Europe represented only 18.4% of full-year 2025 capital, while North America dominated with 77.5%. In year-to-date 2026, Europe has moved ahead of North America by capital and deal count.

Asia-Pacific is also gaining modest visibility from a smaller base. The region produced 2 year-to-date 2026 deals and captured 9.5% of capital, up from 3.4% of full-year 2025 capital. Cauldron Ferm and StrainX Bioworks show that manufacturing and precision-fermentation infrastructure are becoming more visible outside the US-Europe axis.

The strongest regional momentum belongs to Europe. The synthetic biology market has become more transatlantic in 2026, with APAC adding a smaller but meaningful manufacturing and food-linked signal.

For more regional detail, see the market report covering synthetic biology geography.

Which regions are losing momentum in synthetic biology funding?

North America is losing relative momentum in the synthetic biology market so far in 2026, even though it remains a major funding region. North America captured $113.9M, or 41.2% of year-to-date 2026 capital, down from $292.9M and 72.0% over the comparable 2025 period.

The decline is relative, not absolute abandonment. North America still produced 7 year-to-date 2026 deals, compared with 8 over the comparable 2025 period, so the region has not stopped producing fundable synthetic biology companies.

The issue is round size and concentration. The comparable 2025 period included several large North American rounds in therapeutics and engineered microbes, including Stylus Medicine, Arbor Biotechnologies, Antheia, Grove Biopharma, and Synthetic Design Lab. Year-to-date 2026 has Think Bioscience and other meaningful North American rounds, but fewer very large North American financings overall.

Latin America, the Middle East, and Africa are not clearly losing momentum because the prior base was already very small. Their absence in year-to-date 2026 is better read as continued lack of disclosed qualifying pure-play equity rounds above the threshold, not as evidence that local science activity disappeared.

The main region losing relative momentum is North America. The synthetic biology market remains highly relevant there, especially in therapeutics, but the 2026 funding map is much less US-centric than the 2025 funding map.

Is the synthetic biology market becoming more global or more regionally concentrated?

The synthetic biology market is becoming less North America-concentrated in 2026, but it is not yet truly global. Year-to-date 2026 capital is split across Europe at 49.3%, North America at 41.2%, and Asia-Pacific at 9.5%.

That is meaningfully more balanced than full-year 2025, when North America alone captured 77.5% of qualifying capital. The 2026 deal count is also more balanced, with Europe at 8 deals, North America at 7, and Asia-Pacific at 2.

But a balanced transatlantic market is not the same as a global market. Latin America, the Middle East, and Africa had zero qualifying year-to-date 2026 deals. Full-year 2025 had one Middle East deal and one Africa deal, but those were too small to change the overall structure.

The longer pattern is still concentrated. North America and Europe together captured 96.1% of 2024 capital, 95.9% of 2025 capital, and 90.5% of year-to-date 2026 capital. Asia-Pacific is becoming more visible, but the synthetic biology market remains concentrated in mature deeptech venture ecosystems.

The better interpretation is that the synthetic biology market is becoming more transatlantic rather than truly global. Europe has gained enough strength to challenge North American dominance, while APAC remains a selective but not yet broad capital center.

This chart, featured in our synthetic biology market deck, shows how DNA tool adoption has driven growth in the synthetic biology market over time

Is synthetic biology capital moving toward proven winners or new opportunities?

Synthetic biology capital is moving toward proven winners in 2026, even though new opportunities are still entering the funnel. First financings represented 35.3% of year-to-date 2026 deals but only 11.2% of capital.

That means the market is still forming companies, but the capital-weighted market is favoring follow-on rounds. Large checks are going to companies that have already passed earlier screens around technical feasibility, market relevance, regulatory path, or manufacturing progress.

This is a major shift from the comparable 2025 period. Over the comparable 2025 window, first financings were 50.0% of deals and captured 49.4% of capital. The 2025 period included several large first financings and company launches, which made new opportunities unusually important.

The category evidence points in the same direction. Most year-to-date 2026 food-platform capital went to follow-ons such as Verley, Standing Ovation, and Clean Food Group. The largest therapeutics dollars went to follow-on or later-stage companies such as bit.bio, Think Bioscience, and Syntax Bio.

The strongest reading is that synthetic biology investors are not rejecting new opportunities, but they are reserving large checks for companies with prior validation. The market has moved from broad company formation toward milestone selection.

Is the synthetic biology market becoming winner-takes-most?

The synthetic biology market is winner-takes-most in capital allocation, but it is not winner-takes-all around one company. Year-to-date 2026 top-3 rounds captured 48.8% of capital, and the top-10 rounds captured 89.2%.

That is a highly concentrated funding structure. The bottom half of year-to-date 2026 deals captured only 14.0% of capital, which means the long tail matters for company formation but does not drive the funding total.

At the same time, the market is less dominated by one single mega-round than many deeptech categories. The largest year-to-date 2026 round captured 19.9% of total capital, compared with 20.9% over the comparable 2025 period and 13.4% in full-year 2025.

The full-year comparison shows that 2025 was less top-heavy than 2024 by several measures. The top deal captured 13.4% of 2025 capital versus 22.1% in 2024, and the top 3 captured 34.6% versus 42.8%.

The synthetic biology market is therefore not collapsing into a single champion, but it is clearly rewarding a small group of validated companies disproportionately. Funding headlines should always be read with the top-3 and top-10 concentration shares in mind.

For concentration metrics and company-level drivers, see the full market view on synthetic biology funding concentration.

Is the next wave of synthetic biology winners becoming visible?

Yes, the next wave of synthetic biology winners is becoming visible, but the signal is strongest in therapeutics, precision-fermentation food, engineered microbes, and manufacturing infrastructure. The current funding pattern highlights companies that can connect engineered biology to measurable clinical, ingredient, industrial, or manufacturing outcomes.

The most visible year-to-date 2026 candidates are not defined only by large round size. They are defined by the bottlenecks they address: cell programming, synthetic-biology-enabled therapeutics, precision-fermentation dairy proteins, pharmaceutical ingredient biomanufacturing, continuous fermentation, optogenetic fermentation control, and microbial production platforms.

The 2025 comparison helps separate durable themes from short-term noise. In 2025, Synthetic Biology Therapeutics and Synbio Design Software led capital. In 2026, therapeutics remains dominant, while design software has faded sharply. That suggests the next wave is currently more visible in therapeutics and production-oriented platforms than in pure AI-biology software.

Food-platform winners are becoming clearer, but the signal is selective. The strongest food financings are not generic alternative-protein stories; they are precision-fermentation or biomolecule platforms with specific product targets such as dairy proteins, casein, oils, fats, melanin, and sweet proteins.

The answer is yes, with caution. The next winners are visible enough to identify proof patterns, but not broad enough to declare a full-sector breakout. The likely winners are companies that translate synthetic biology into measurable performance improvements in clinical, ingredient, manufacturing, or industrial contexts.

As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly

Is the synthetic biology funding landscape fragmenting or consolidating?

The synthetic biology funding landscape is fragmenting by investor base and application area, while consolidating around a smaller set of proof standards. Year-to-date 2026 had about 90 unique disclosed investors across 17 deals, but only SOSV and Good Startup appeared in more than one qualifying deal.

That points to investor fragmentation. Many investors are willing to participate in synthetic biology rounds, but few are repeatedly leading or anchoring multiple deals across the market.

The category landscape is also fragmented. Year-to-date 2026 deals are spread across all six categories, with Food Platforms and Engineered Microbes at 4 deals each, Therapeutics and Biofoundry Platforms at 3 each, Materials at 2, and Design Software at 1.

But the capital side is more disciplined. Synthetic Biology Therapeutics captured 43.2% of year-to-date 2026 capital from only 17.6% of deals, while larger checks in other categories tended to attach to production readiness, regulated use cases, or customer demand.

The best description is horizontal fragmentation and vertical discipline. Many investors and subcategories remain active, but the biggest checks are consolidating around companies with credible proof of clinical relevance, cell-programming capability, manufacturing economics, or specific high-value molecules.

Where is investor attention shifting in synthetic biology?

Investor attention in the synthetic biology market is shifting toward measurable bottlenecks: therapeutics, cell programming, manufacturing scale-up, precision fermentation economics, engineered-microbe productivity, and biological design tools with direct deployment paths. The strongest current signal is that Synthetic Biology Therapeutics captured 43.2% of year-to-date 2026 capital.

The biggest shift is away from pure Synbio Design Software dominance. In 2024, Synbio Design Software captured 40.0% of capital, and in 2025 it captured 29.2%. In year-to-date 2026, it captured only 3.4%.

That does not mean biological design has become irrelevant. It means investors are putting more weight on whether design capability connects to products, therapies, manufacturing workflows, or clear customer demand. Model quality alone is no longer enough as a financing narrative.

Therapeutics are now the clearest capital magnet. Synthetic Biology Therapeutics led full-year 2025 with 37.1% of capital and leads year-to-date 2026 with 43.2%. That continuity suggests investors increasingly prefer synthetic biology applications where technical proof can translate into high-value clinical assets.

Food platforms and engineered microbes are receiving sustained attention, but the attention is more disciplined. Investors are backing specific proteins, molecules, ingredients, production systems, and industrial use cases rather than broad “bio-based future” stories.

The core shift is toward synthetic biology that solves named constraints. The strongest funding cases explain how a platform reduces biological design time, improves fermentation control, produces a high-value molecule, enables a clinical program, replaces a constrained input, or improves manufacturing economics.

For the complete category-by-category funding view, see the synthetic biology market report.

This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.